Table 1 Baseline characteristics of patients

From: Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications

  

Drug therapies

N (%)

N (male/female)

223 (149/74)

Antidiabetics

 

Age (y/o)

58.1 ± 0.8

DPP-4 inhibitors

164 (73.5%)

Body weight (kg)

77.9 ± 1.5

Metformin

126 (56.5%)

BMI (kg/m2)

28.4 ± 0.5

Sulfonylurea

16 (7.2%)

HbA1c (%)

7.89 ± 0.08

GLP-1 agonists

10 (4.5%)

LDL-cholesterol (mg/dL)

108.4 ± 6.4

Insulin

65 (29.1%)

  

Antihypertensives

 

eGFR (mL/min/1.73 m2)

N (%)

RAS inhibitors

114 (51.1%)

≥90

44 (19.7%)

ARB

69 (30.9%)

90 > ≥60

120 (53.8%)

ACE inhibitors

45 (20.2%)

60 > ≥45

38 (17.0%)

Ca channel blockers

87 (39.0%)

45 > ≥30

13 (5.8%)

β blockers

45 (20.2%)

30 > 

8 (3.6%)

Diuretics

22 (9.9%)

  

Loop

18 (8.1%)

  

Thiazides

4 (1.8%)

Back to article page